Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic delivery.
about
Generating orally active galanin analogues with analgesic activitiesEfficacy and tolerability of the galanin analog NAX 5055 in the multiple-hit rat model of symptomatic infantile spasms.GalR2-positive allosteric modulator exhibits anticonvulsant effects in animal models.Synthesis and biological evaluation of novel pyrimidine derivatives as sub-micromolar affinity ligands of GalR2.The generation of knock-in mice expressing fluorescently tagged galanin receptors 1 and 2.Galanin receptors and ligands.Anticonvulsant neuropeptides as drug leads for neurological diseases.The role of locus coeruleus in the antiepileptic activity induced by vagus nerve stimulation.Analgesic neuropeptide W suppresses seizures in the brain revealed by rational repositioning and peptide engineering.Are GPCRs still a source of new targets?Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII).Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics.A resurging boom in new drugs for epilepsy and brain disorders.Preclinical evaluation of intravenous NAX 810-2, a novel GalR2-preferring analog, for anticonvulsant efficacy and pharmacokinetics.G-protein-coupled receptor-mediated MAPK and PI3-kinase signaling is maintained in Chinese hamster ovary cells after γ-irradiation.Preclinical Analgesic and Safety Evaluation of the GalR2-preferring Analog, NAX 810-2.
P2860
Q28260945-0859E9BC-172F-4670-97EF-6FF114B9BBB9Q30560643-CDC24F9B-EA40-4765-B7AB-9F715EFFA718Q34093567-BB563A9A-5E15-45F8-8959-968F6B399C77Q35753039-B90A75B3-773F-4FB8-8120-9134F22B1364Q36159591-6C595C49-1D4B-4441-A80C-177F04B9140FQ36451712-34BA0C4F-EEE2-49A7-9ED0-AE29EADBF78AQ37845684-E5DFE3C8-C89C-4165-89F7-49DF191E8EFCQ37871070-D3EA20E4-9B8E-4292-BD19-F795FF79322AQ38028949-7FA45CD2-2F47-4D12-890A-965522CB5BEAQ38129012-49D6B7C3-B4E1-48DB-AFE3-D2954F7A3255Q39006241-F5E3B531-C120-4528-9546-8DC1CE7F8E97Q47590580-CFC3D936-377B-49F0-8FB0-38340FB227DCQ48093388-98A5B268-234E-420E-AFC8-56202363E978Q48352136-105A8284-7134-430B-9764-C11424B72BCFQ51763940-811ED979-1586-43FE-9518-4A9B9D1207E7Q52099813-8A6DE6EE-CCF3-4EC5-92EB-10C87BD1BE4E
P2860
Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic delivery.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Engineering galanin analogues ...... y following systemic delivery.
@en
Engineering galanin analogues ...... y following systemic delivery.
@nl
type
label
Engineering galanin analogues ...... y following systemic delivery.
@en
Engineering galanin analogues ...... y following systemic delivery.
@nl
prefLabel
Engineering galanin analogues ...... y following systemic delivery.
@en
Engineering galanin analogues ...... y following systemic delivery.
@nl
P2093
P2860
P356
P1476
Engineering galanin analogues ...... y following systemic delivery.
@en
P2093
Brad R Green
Charles R Robertson
Erika Adkins Scholl
Grzegorz Bulaj
H Steve White
Timothy H Pruess
P2860
P304
P356
10.1021/JM9018349
P407
P577
2010-02-01T00:00:00Z